Merck and Isomorphic Labs to Collaborate on AI-Driven Cancer Drug Discovery
MRK Merck & Co Inc
$137.78 -3.90%
View chart & analysis → - 1Merck has launched a research collaboration with Isomorphic Labs to discover small molecule cancer treatments using artificial intelligence.
- 2Isomorphic Labs will perform molecular design by applying its proprietary AI drug design engine, IsoDDE.
- 3Founded in 2021, Isomorphic Labs will handle computation-based drug discovery, while Merck will be responsible for subsequent development and commercialization.
So what's the key point?
Merck has started research to create cancer treatments alongside Isomorphic Labs, a company with artificial intelligence technology. Isomorphic Labs uses AI to design the drugs, and Merck will take on the role of developing and selling them.
Source Nasdaq +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.